IP Library › Granted Patent US 9,539,331
Granted Patent B2
US 9,539,331 · App. 14/365,841 · Granted Jan 10, 2017

Preparations containing amorphous emodepside

Inventors: Venkata-Rangarao Kanikanti (Leverkusen, DE); Petra Lange (Essen, DE); Hans-Jürgen Hamann (Dormagen, DE); Peter Kleinebudde (Düsseldorf, DE)
Assignee: Bayer Intellectual Property GmbH
A61K47/32A61K9/146A61K38/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,539,331
App. No.
14/365,841
Granted
Jan 10, 2017
Kind
B2
Abstract

The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.

Claims (10)

1. Preparation comprising emodepside in a polyvinylpyrrolidone matrix, characterized in that at least 50% by weight of the emodepside is in an amorphous form and the preparation is either of melt extrudate or a coprecipitate.

2. Preparation according to claim 1 , additionally comprising a surfactant.

3. Preparation according to claim 1 , characterized in that it is a melt extrudate.

4. Preparation according to claim 1 , characterized in that it is a coprecipitate.

5. A pharmaceutical composition comprising a preparation according to any one of the preceding claims and a pharmaceutically acceptable adjuvant.

6. A method for the control of an endoparasite in a human or animal comprising administering to a human or animal in need thereof a pharmaceutical composition according to claim 5 .

7. The method according to claim 6 wherein the endoparasite is Dirofilaria immitis.

8. Preparation according to claim 1 , characterized in that at least 70% by weight of the emodepside is in an amorphous form.

9. Preparation according to claim 1 , characterized in that at least 80% by weight of the emodepside is in an amorphous form.

10. Preparation according to claim 1 , characterized in that at least 90% by weight of the emodepside is in an amorphous form.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2018
From: BAYER INTELLECTUAL PROPERTY GMBH
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 046842/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2014
From: KANIKANTI, VENKATA-RANGARAO, DR.; LANGE, PETRA; HAMANN, HANS-JUERGEN, DR.; KLEINEBUDDE, PETER, DR.
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 033599/0027 →
Priority Claims (1)
EP 11194878 · Dec 21, 2011 · regional
Continuity (1)
Related Publication 20140371139A1 · Dec 18, 2014